The hemorrhage risk of dasatinib therapy

In this issue of Blood, Kaiser et al(1) pinpoint the glycoprotein IIb (GPIIB)/G alpha(13)/Src tyrosine kinase (c-Src)/14-3-3 zeta signaling axis as a requirement for platelet migration and shed light on how the antineoplastic oral tyrosine kinase inhibitor dasatinib increases the risk of inflammation-associated mucosal hemorrhage.

Automated summary

In this study, the glycoprotein IIb (GPIIb)/G alpha(13)/Src tyrosine kinase (c-Src)/14-3-3 zeta signaling axis was identified as necessary for platelet migration. The research also sheds light on the mechanism by which the antineoplastic oral tyrosine kinase inhibitor dasatinib increases the risk of inflammation-associated mucosal hemorrhage.